RCM Technologies, Inc. (RCMT) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 28, 2025 (13 weeks) and the year-to-date period ended June 28, 2025 (26 weeks). RCM Technologies, Inc. provides business and technology solutions through three primary segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions. The company operates globally with significant revenue concentration in the United States.
Key Financial Metrics (26 Weeks Ended June 28, 2025)
| Metric | Current Period (26 Weeks) | Prior Period (26 Weeks) |
|---|---|---|
| Revenue | $162.6 million | $141.1 million |
| Net Income | $8.0 million | $7.7 million |
| Diluted EPS | $1.04 | $0.95 |
| Operating Income | $13.2 million | $11.7 million |
| Gross Margin | 27.2% | 28.6% |
| Cash from Operations | $8.8 million | $12.2 million |
| Debt (Line of Credit) | $34.0 million | $35.0 million |
| Cash & Equivalents | $5.5 million | $4.7 million (Year End) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15.2% year-over-year (YTD), driven by strong performance in the Specialty Health Care (+14.6%) and Engineering (+27.5%) segments. The Life Sciences segment declined 10.5% due to project timing and a strategic deemphasis on legacy staffing.
- Margin Compression: Gross margin decreased to 27.2% from 28.6% in the prior year. This was primarily due to a mix shift toward lower-margin Engineering EPC (Engineering, Procurement, and Construction) projects and Aerospace work.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased to $30.2 million (18.6% of revenue) from $27.7 million (19.8% of revenue). While absolute costs rose due to inflation and equity compensation, the expense ratio improved.
- Cash Flow: Operating cash flow decreased to $8.8 million from $12.2 million. This was largely due to a $5.8 million increase in accounts receivable, attributed to procedural payment delays from school clients and normal fluctuations in EPC projects.
- Tax Rate: The effective income tax rate increased to 31.0% from 27.6%, driven by permanent tax differences in the United States.
Guidance, Outlook, and Risks
- Outlook: Management expects continued demand for outsourcing in life sciences, IT, and engineering. The company is focusing on high-margin project work and optimizing its business model.
- Capital Allocation: The company continues its share repurchase program. As of June 28, 2025, $37.1 million remained available under the $50.0 million authorization. No shares were sold under the At-The-Market (ATM) program to date.
- Liquidity: The company maintains a $65.0 million revolving credit facility with $20.8 million available. Management believes current resources are sufficient for the next 12 months.
- Risks:
- Customer Concentration: Two customers accounted for 22.5% and 13.1% of revenue in the first half of 2025, both within the Specialty Health Care segment.
- Regulatory & Economic: Risks include changes in healthcare regulations, minimum wage increases, and general economic downturns affecting client spending.
- Legal: The company has accrued $1.1 million for asserted claims but believes no material adverse effect is likely.
Investor Verification Checklist
- Verify the status of payment collections from the two major school clients cited as causing accounts receivable delays.
- Monitor the mix of Engineering revenue between high-margin consulting and lower-margin EPC projects to assess future margin trends.
- Review the progress of the Life Sciences segment's transition away from legacy staffing to determine if revenue declines will stabilize.
- Track the utilization of the $37.1 million remaining share repurchase authorization.
- Assess the impact of the increased effective tax rate on future net income projections.